Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports

Einar S. Björnsson1,2 | Inmaculada Medina-Caliz3 | Raul J. Andrade3,4 | M. Isabel Lucena3,4

1Faculty of Medicine, University of Iceland, Reykjavik, Iceland
2Division of Gastroenterology and Hepatology, Department of Internal Medicine, The National University Hospital of Iceland, Reykjavik, Iceland
3UGC Aparato Digestivo and Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain

Correspondence
Einar S. Björnsson, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The National University Hospital of Iceland, Hringbraut, 101 Reykjavik, Iceland.
Email: einarsb@landspitali.is

Funding information
Supported by grants of Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional-FEDER (contract number: PI19-00883)

Abstract
Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune-like hepatitis (DI-AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to define and review the published evidence of suspected DI-AILH. Search was undertaken in Pubmed using search terms “drug-induced liver injury,” “autoimmune hepatitis,” and “drug-induced autoimmune hepatitis.” DI-AILH was defined as (1) drug as a potential trigger of liver injury with autoimmune features and histological findings compatible with AIH; (2) no or incomplete recovery or worsening of liver tests after discontinuation of the drug; (3) corticosteroids requirement or spontaneous recovery; (4) follow-up without immunosuppression (IS) and no relapse of AIH at least 6 months after discontinuation of IS; and (5) drugs potentially inducing AILH with a chronic course. Cases fulfilling the first four criteria were considered probable DI-AILH with three possible DI-AILH. A total of 186 case reports were identified for conventional drugs (n = 148; females 79%; latency 2.6 months) and HDS (n = 38; females 50%). The most commonly reported agents of DI-AILH were interferons (n = 37), statins (n = 24), methylprednisolone (MPS) (n = 16), adalimumab (n = 10), imatinib (n = 8), and diclofenac (n = 7). Tinospora cordifolia and Khat were the only HDS with probable DI-AILH cases. No relapses of AIH were observed when IS was stopped after interferons, imatinib, diclofenac, and methylprednisolone. Conclusion: Beyond well-recognized nitrofurantoin, methyldopa, hydralazine, minocycline, and infliximab as causes of DI-AILH, interferons, imatinib, adalimumab, and MPS were the best-documented agents leading to probable DI-AILH. Khat and Tinospora cordifolia were the only HDS found to be able to induce DI-AILH. Long-term immunosuppression appears to be rarely required in patients with DI-AILH due to these drugs.
INTRODUCTION

Drug-induced autoimmune-like hepatitis (DI-AILH) is an emerging phenotype of hepatotoxicity traditionally related to a number of specific drugs such as hydralazine, methyldopa, nitrofurantoin, minocycline, and infliximab, and with HDS such as black cohosh.\(^1\) There is at the current time no agreement on the definitions.\(^9\) Autoantibodies can be found in many liver disorders other than autoimmune hepatitis (AIH), such as acute liver failure,\(^12\) acute idiosyncratic DILI,\(^13,14\) liver injury due to HDS,\(^15\) and in chronic liver diseases.\(^16\) Thus, autoantibodies are often secondary to liver injury, and it can be difficult to ascertain whether autoimmune mechanisms are involved in the pathogenesis of the liver injury.

In one study, patients with DI-AILH due to nitrofurantoin and minocycline had very similar clinical, immunological, and histological features as those with idiopathic AIH, except lack of relapse after discontinuation of corticosteroids.\(^5\) This has also been seen with hydralazine, methyldopa and infliximab, as liver injury with autoimmune features due to these drugs does not usually relapse after patients enter biochemical remission.\(^7,19\) More than 30 drugs have been suspected to lead to DI-AILH, but for many of these drugs, the documented evidence is limited and consists of a single report.\(^9,22,23\)

The terminology used to describe what we have chosen to call DI-AIH is controversial. It has also been called “drug-induced autoimmune-like hepatitis,”\(^9\) “immune-mediated DILI,”\(^24\) and “drug-induced liver injury with autoimmune features.”\(^25\) Although drug-induced AIH (DI-AIH) has been most frequently used in recent literature,\(^5,10,26\) it is still controversial and we have therefore chosen to name this condition, drug-induced autoimmune-like hepatitis (DI-AILH).

Criteria for DI-AILH have been largely lacking. The aim of the study was to establish a set of criteria to define DI-AILH and to review the literature and analyze the suspected cases of this clinical phenotype following these predefined criteria.

METHODS

Search was undertaken in Pubmed (pubmed.ncbi.nlm.nih.gov) on “drug-induced liver injury,” “autoimmune hepatitis,” and “drug-induced autoimmune hepatitis” until 2021. References cited in the articles that were identified through the literature search were reviewed to retrieve additional case reports.

Published case reports and case series on DI-AILH were analyzed. Case reports with drugs or HDS suspected to have induced AIH-like picture were reviewed and the following information obtained: age, gender, suspected drug or HDS, duration of drug therapy, antinuclear antibodies (ANAs), anti-smooth muscle antibodies (SMAs), IgG levels, liver biopsy, and whether the histology was compatible with AIH. From these results, the new simplified score for AIH was calculated.\(^29\) Liver biopsy results were registered in accordance with the Hennes et al. paper.\(^29\) Information was also obtained on whether drug discontinuation led to improvement in liver tests or whether there was incomplete recovery after discontinuation of the implicated drug. Information was registered on the use of corticosteroids and other immunosuppressive therapies (IS). Information on the dose of corticosteroids was often missing, and when it was provided it was very heterogeneous in the different case reports and seemed to be according to the standard of care for use in idiopathic AIH. Importantly, whether IS had been discontinued, and if the patient had experienced a relapse, and what the duration of follow-up was in months, was determined. Patients who were still on IS at the time of the case report were not excluded, but the case could only be according to our definition a possible DI-AILH. In other words, they lacked complete documentation that provided evidence of a probable DI-AILH. References from all case reports that were analyzed are found in the Supporting Information.

DI-AILH was defined as follows:

1. Drug as a potential trigger of liver injury with autoimmune features and histological findings compatible with AIH: elevation in any of ANAs, SMAs and IgG, and a liver biopsy compatible with AIH, as stated in the paper by Hennes et al. on the new simplified criteria (NSC).\(^29\) Thus, it was not enough to have either positive ANA/SMA/IgG or a liver biopsy compatible with AIH.
2. No or incomplete recovery or worsening of liver tests after discontinuation of the drug.
3. Corticosteroids requirement for or spontaneous recovery of AIH. Although there was in some cases spontaneous recovery, it was prolonged, taking many weeks (not contradicting criteria 2).
4. Follow-up without IS and no relapse of AIH at least 6 months after discontinuation of IS.
5. Drugs potentially inducing AILH with a chronic course

Published clinical case reports with at least two convincing reports fulfilling three of the first four criteria were considered possible DI-AILH, and all four criteria as probable DI-AILH. Relapse of AIH was analyzed after discontinuation of IS when that was tried. DI-AILH due to nitrofurantoin, methyldopa, hydralazine, minocycline, and infliximab was excluded, as was liver injury associated with immune checkpoint inhibitors.

RESULTS

A total of 186 case reports were identified for conventional drugs (\(n = 148\)) and HDS (\(n = 38\)).
The most commonly reported class of agents leading to DI-AILH were interferons, (n = 39), statins (n = 24), methylprednisolone (n = 16), imatinib (n = 10), adalimumab (n = 10), and diclofenac (n = 7). Drugs included two cases, efalizumab and etanercept, and 38 reports with single reports or more but not fulfilling the criteria of DI-AILH in at least two reports.

**Interferons**

A total of 39 case reports with interferon-induced liver injury were retrieved; two were excluded due to the lack of data (Supporting Information [SI] 1 and 2), but 17 publications contained 37 case reports (SI 3–19). Females made up 32 of 37 (86%); median age of 38 years (range 11–68) (Table 1). Indications for interferon alpha was hepatitis non-A, non-B, hepatitis C (n = 14) and interferon beta, indication multiple sclerosis (n = 23). The median duration of interferon therapy was 3 months. In none of the reports from 1989 to 2004, discontinuation of IS was attempted (Table 1). Since 2006, when IS was reported to have been stopped, all of that were tried (n = 8) were successful (Table 1). Thus, eight cases of interferon fulfilled all criteria for probable DI-AILH (Table 1). In none of the case reports was there a relapse after patients entered biochemical remission, and therefore did not fulfill criteria 5 of being able to induce chronic self-perpetuating AIH.

**Statins**

A total of 24 cases of statin DI-AILH were retrieved (SI 20–31), which consisted mostly of atorvastatin (n = 11) (Table 2). Females made up 67% of the patients (median age 58 years and 4 months duration [range 1.5–62 months]). Relapse after corticosteroids discontinuation was commonly observed (n = 7). Only 4 of 24 (17%) fulfilled the criteria for probable DI-AILH-like (Table 2). A total of seven case reports of statin-induced DI-AILH phenotype fulfilled criteria 5, suggesting that statins might trigger classical AIH, with atorvastatin (n = 3), simvastatin (n = 3) and rosuvastatin (Table 2).

**Imatinib and other kinase inhibitors**

A total of eight cases with imatinib were reported (6 females [75%; SI 32–39]; median age of 57 years [range 27–68]; and 3 months duration of therapy) (Table 3). None of the patient who discontinued corticosteroids had relapse of DI-AILH. Masitinib and pazopanib seemed to cause a similar DI-AILH (Table 3). In none of the case reports was there a relapse reported after patients entered biochemical remission, and therefore did not fulfill criteria 5 of being able to trigger classical AIH.

**Adalimumab, etanercept, and efalizumab**

In 10 case reports adalimumab was believed to have induced DI-AILH (SI 39–46). A total of 9 of 10 (90%) were female (median age of 43 years; 3 months of therapy) (Table 4). Most patients continued on corticosteroids, but in 2 of 3 patients no relapse was observed after stopping immunosuppression. Convincing cases of DI-AILH were found to be associated with etanercept and efalizumab (SI 47–49), but in all of these patients corticosteroid therapy was maintained (Table 4). One patient had a mild relapse (SI 45), and it is conceivable that adalimumab might trigger or induce classic AIH, as it fulfilled criteria 5 in this case.

**Diclofenac**

Seven patients were suspected of DI-AILH (Table 5). All except 1 was from the early 1990s and based on only three reports (SI 29 and 50–51). Most were female (median age of 46 years; 2.5 months of therapy). In 4 of these patients with autoimmune features, corticosteroids were required; and in 3 of these patients corticosteroids were discontinued without evidence of relapse. In none of the case reports was there a relapse after patients entered biochemical remission.

**Methylprednisolone**

Methylprednisolone (MPS) given intravenously in high pulses has been associated with liver injury with autoimmune features, and a total 16 cases were retrieved (SI 52–55). Most (94%) were of female gender. IS was stopped in 13 of 16 (81%) patients, and none of these patients were found to experience a relapse of DI-AILH (Table 6). In none of the case reports was there a relapse after patients entered biochemical remission, and MPS was not reported to induce AIH phenotype with a chronic course.

**Herbal and dietary supplements**

Only four different agents were retrieved: germander, black cohosh, khat, and Tinospora cordifolia (SI 56–62). None of the reports with suspected of DI-AILH due to germander (56) and black cohosh (SI 57 and 58) fulfilled the criteria for probable DI-AILH (Table 7). Two reports with turmeric were identified (SI 59 and 60) that
TABLE 1 Suspected DI-AILH associated with interferons

| Age, years/gender, F/M | Drug            | Duration (months) | ANA | SMA | IgG high | Biopsy | Cortico-steroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
|-----------------------|-----------------|-------------------|-----|-----|----------|--------|------------------|---------|---------|-----|-----|------------|----------------------|
| Vento 1989 (SI 3)     | Interferon alfa | 1                 | Pos | Pos | Yes      | Yes    | Yes              | Pos     | No      | 8   | 6   | Yes         | 1,2,3                 |
| Vento 1989 (SM 3)     | Interferon alfa | 1.5               | Pos | Neg | Yes      | Yes    | Yes              | Yes     | No      | 7   | 24  | Yes         | 1,2,3                 |
| Silva 1991 (SI 4)     | Interferon alfa | 4                 | Pos | Pos | N/A      | Yes    | Yes              | No      | No      | 5   | 6   | Yes         | 1,2,3                 |
| Ruiz- Moreno 1991 (SI 5) | Interferon alfa | 3                | Pos | Neg | Yes      | No     | Yes              | Yes     | No      | 5   | 4   | Yes         | 1,2,3                 |
| Shindo 1992 (SI 6)    | Interferon alfa | 0.5               | Pos | Neg | N/A      | Yes    | Yes              | No      | No      | 4   | –   | Yes         | 1,2,3                 |
| Papo 1992 (SI 7)      | Interferon alfa | 3                 | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | 6   | –   | Yes         | 1,2,3                 |
| Papo 1992 (SI 7)      | Interferon alfa | 1                 | Pos | Pos | No       | Yes    | Yes              | No      | No      | 5   | –   | Yes         | 1,2,3                 |
| Papo 1992 (SI 7)      | Interferon alfa | 1                 | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | 6   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Garcia- Buey 1995 (SI 8) | Interferon alfa | N/A               | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | –   | –   | Yes         | 1,2,3                 |
| Durelli 1998 (SI 9)   | Interferon beta | 4.5               | Pos | Pos | No       | No     | Yes              | No      | No      | 3   | 1  | No         | Yes 4                 |
| Durelli 1998 (SI 9)   | Interferon beta | 2                 | Pos | Pos | N/A      | No     | No               | No      | No      | 3   | 2   | Yes         | 4                  |
| Yoshida 2001 (SI 10) | Interferon beta | 2                 | Neg | Neg | N/A      | Yes    | Yes              | No      | No      | 2   | –   | Yes         | 1,2,3                 |
| Duchini 2002 (SI 11)  | Interferon beta | 24                | Pos | Pos | Yes      | Yes    | Yes              | Yes     | No      | 7   | –   | Yes         | 1,2,3                 |
| Wallack 2004 (SI 12)  | Interferon beta | 24                | Pos | Pos | N/A      | No     | Yes              | No      | No      | 4   | –   | Yes         | 1,2,3                 |
| Byrnes 2006 (SI 13)   | Interferon beta | 10                | Pos | Pos | Yes      | Yes    | Yes              | No      | No      | 6   | 10  | No         | 1,2,3,4               |
| Byrnes 2006 (SI 13)   | Interferon beta | 37                | Neg | Neg | Yes      | Yes    | Yes              | Yes     | No      | 5   | –   | Yes         | 1,2,3                 |
**TABLE 1** (Continued)

| Age, years/gender, F/M | Drug           | Duration (months) | ANA | SMA | IgG high | Biopsy | Cortico-steroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
|------------------------|----------------|-------------------|-----|-----|----------|--------|------------------|----------|---------|-----|-----|-------------|----------------------|
| Byrnes 2006 (SI 13)    | 30/F           | Interferon beta   | 2   | Pos | Pos      | No     | Yes              | No       | No      | 5   | –  | No          | 1,2,3,4               |
| Pulicken 2006 (SI 14)  | 43/F           | Interferon beta   | 1,5 | Pos | Pos      | N/A    | Yes              | Yes      | No      | 5   | 7  | No          | 1,2,3,4               |
| Montero 2007 (SI 15)   | 39/F           | Interferon beta   | 60  | Pos | Pos      | N/A    | Yes              | No       | No      | 5   | –  | Yes         | 1,2,3                |
| Kowalec 2014 (SI 16)   | 42/F           | Interferon beta   | 34  | Pos | N/A      | N/A    | No               | No       | No      | 4   | 7  | No          | 1,2,4                |
| Villamil 2014 (SI 17)  | 20/F           | Interferon beta   | 0,75| Neg | Pos      | No     | Yes              | Yes      | No      | 4   | 36 | No          | 1,2,3,4               |
| Villamil 2014 (SI 17)  | 47/M           | Interferon beta   | 1   | Pos | Neg      | No     | Yes              | Yes      | No      | 4   | 36 | No          | 1,2,3,4               |
| Kalafateli 2016 (SI 18)| 57/F           | Interferon beta   | 24  | Pos | Pos      | No     | Yes              | No       | No      | 6   | 36 | No          | 1,2,3,4               |
| Rigopoulou 2018 (SI 19)| 38/F           | Interferon beta   | 11  | Pos | Pos      | No     | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 34/F           | Interferon beta   | 312 | Pos | Pos      | N/A    | Yes              | Yes      | No      | 5   | 72 | No          | 1,2,3,4               |
| Rigopoulou 2018 (SI 19)| 57/F           | Interferon beta   | 24  | Neg | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 34/F           | Interferon beta   | 3   | Pos | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 38/F           | Interferon beta   | 1   | Neg | Pos      | N/A    | Yes              | Yes      | No      | 5   | 104| No          | 1,2,3,4               |
| Rigopoulou 2018 (SI 19)| 31/F           | Interferon beta   | 12  | Pos | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 36/F           | Interferon beta   | 84  | Neg | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 35/F           | Interferon beta   | 2   | Pos | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |
| Rigopoulou 2018 (SI 19)| 37/F           | Interferon beta   | 3   | Neg | Pos      | N/A    | Yes              | Yes      | No      | 5   | –  | Yes         | 1,2,3                |

Abbreviations: ANA, antinuclear antibody; DI-AILH, drug-induced autoimmune-like hepatitis; F, female; F-U, follow-up; IS, immunosuppression; M, male; N/A, not available; Neg, negative; NSC, new simplified criteria for AIH (Ref. 29); Pos, positive; SI, Supporting Information; SMA, smooth muscle antibody.

*Lethal acute liver failure.*
**TABLE 2** Suspected DI-AILH associated with statins

| Age, years/ gender, F/M | Drug       | Duration (months) | ANA | SMA | IgG high | Biopsy | Corticosteroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
|-------------------------|------------|-------------------|-----|-----|----------|--------|-----------------|----------|---------|-----|-----|------------|----------------------|
| Graziadei 2003 (SI 20)  | 58/F       | Atorvastatin      | 7   | Pos | Neg      | Yes    | Yes             | Yes      | Yes     | Yes | 6  | 12         | Yes, 1,2,3            |
| Pelli 2003 (SI 21)      | 65/F       | Atorvastatin      | 3   | Pos | Pos      | Yes    | Yes             | Yes      | No      | No  | 7  | 3          | Yes, 1,2,3            |
| Wolters 2005 (SI 22)    | 46/F       | Rosuvastatin      | 2   | Neg | Pos      | –      | Yes             | Yes      | No      | –   | 6  | 6          | Yes, 1,2,3            |
| Alla 2006 (SI 23)       | 51/F       | Simvastatin       | 4   | Pos | Pos      | Yes    | Yes             | Yes      | Yes     | Yes | 7  | 36         | Yes, 1,2,3            |
| Alla 2006 (SI 23)       | 47/M       | Atorvastatin      | 4   | Pos | Neg      | No     | Yes             | Yes      | Yes     | No  | 5  | 24         | Yes, 1,2,3            |
| Alla 2006 (SI 23)       | 51/M       | Atorvastatin      | 4   | Pos | Pos      | Yes    | Yes             | Yes      | –       | 7   | 6          | Yes, 1,2,3            |
| Lucena 2011 (SI 24)     | 51/F       | Fluvastatin       | 3   | Pos | Pos      | Yes    | No              | No       | No      | 7   | 12         | No, 1,2,4             |
| Russo 2009 (SI 25)      | 52/F       | Atorvastatin      | 2   | Pos | Pos      | Yes    | Yes             | Yes      | Yes     | Yes | 6  | -          | Yes, 1,2,3            |
| Russo 2014 (SI 26)      | 71/M       | Atorvastatin      | 42  | Pos | Pos      | Yes    | Yes             | No       | No      | 7   | 12         | Yes, 1,2,3            |
| Russo 2014 (SI 26)      | 61/F       | Atorvastatin      | 62  | Pos | –        | –      | –               | Yes      | Yes     | No  | 7  | 20         | No, 1,2,3,4           |
| Russo 2014 (SI 26)      | 75/F       | Fluvastatin       | 37  | –   | –        | –      | –               | –        | –       | 10  | Yes        | Yes, 1,2,3            |
| Russo 2014 (SI 26)      | 53/F       | Pravastatin       | 12  | –   | –        | –      | –               | –        | –       | –   | –          | Yes, 1,2,4            |
| Russo 2014 (SI 26)      | 58/F       | Rosuvastatin      | 3   | Pos | Pos      | Yes    | Yes             | Yes      | No      | Yes | – | –          | –, 1,2,4              |
| Russo 2014 (SI 26)      | 43/M       | Simvastatin       | 7   | –   | –        | –      | –               | –        | –       | 7   | 11         | Yes, 1,2,3            |
| Perdices 2014 (SI 27)   | 67/F       | Atorvastin        | 3   | Pos | Pos      | Yes    | No              | No       | No      | 8   | 36         | No, 1,2,4             |
| Perdices 2014 (SI 27)   | 63/M       | Atorvastin        | 24  | Pos | N/A      | N/A    | No              | No       | No      | No  | 4  | 7          | No, 1,2,4             |
| Perdices 2014 (SI 27)   | 67/F       | Simvastatin       | 2   | Pos | Pos      | No     | Yes             | Yes      | Yes     | Yes | 5  | 2          | No, 1,2,3,4           |
| Perdices 2014 (SI 27)   | 67/M       | Fluvastatin       | 4   | Pos | Neg      | Yes    | Yes             | Yes      | Yes     | No  | 6  | 96         | No, 1,2,3,4           |
| Sanchez 2018 (SI 28)    | 47/M       | Rosuvastatin      | 11  | Pos | Pos      | No     | No              | No       | No      | No  | 4  | 12         | No, 1,2,4             |
| Yeong 2016 (SI 29)      | 63/F       | Simvastatin       | 18  | Pos | N/A      | N/A    | Yes             | Yes      | Yes     | No  | – | –          | Yes, 1,2,3            |
| Yeong 2016 (SI 29)      | 69/F       | Simvastatin       | 36  | Pos | N/A      | N/A    | Yes             | Yes      | No      | Yes | – | 16         | Yes, 1,2,3            |
| Yeong 2016 (SI 29)      | 78/F       | Atorvastatin      | 19  | Pos | N/A      | N/A    | Yes             | No       | Yes     | –   | 36 | Yes        | Yes, 1,2,3            |
| Shah 2019 (SI 30)       | 47/M       | Rosuvastin        | 1,5 | Neg | Neg      | No     | Yes             | Yes      | No      | No  | 2  | 12         | No, 1,2,3,4           |
| Khan 2020 (SI 31)       | 57/F       | Atorvastin        | 3   | Pos | Pos      | No     | No              | No       | No      | No  | 3  | 18         | No, 1,2,4             |
were (according to the criteria) possible DI-AILH, which recovered relatively quickly after discontinuation of turmeric and did not require corticosteroids. Drawbacks of the case reports were lack of exclusion of hepatitis E (SI 59) and a very short follow-up (SI 60).

A total of 11 reports associated with khat (all males) were identified (SI 61 and 62). In a case series (SI 61), three cases fulfilled the criteria for probable DI-AILH. One patient had only 3 months of follow-up (Table 7).

In two recent papers from India (SI 63 and 64), Tinospora cordifolia was associated with liver injury with prominent autoimmune features in a total of eight cases (7 women) (Table 7). Three cases fulfilled the criteria for probable DI-AILH associated with Tinospora cordifolia. In only one of the case reports of HDS with at least two convincing cases reported was there a relapse after patients entered biochemical remission, which was in a case report with black cohosh (SM57), which fulfilled criteria 5 of being able to induce chronic self-perpetuating AIH.

A variety of different HDS have been associated with DI-AILH in single cases, such as Dai-saiko-to, Ma Huang, N-nitroso-fenfluramine, glucosamine/chondroitin, echinacea, camellia sinensis, and Xiang-tian-guo (SI 65–71). In none of these reports did cases of probable DI-AILH fulfill the criteria (data not shown).

Other case reports

Many drugs have been reported to have induced AIH-like phenotype. These were reported as early as 1971 until 2021. The following drugs were implicated with one or two reports, but not fulfilling criteria for DI-AILH for at least two cases, with a total of 38 case reports: oxyphenisatin ($n = 7$), sulfamethoxypyridazin, propylthiouracil ($n = 2$), dantrolene, perhexiline, clometacin ($n = 2$), amiodarone, pemoline ($n = 2$), meloxicam, moxifloxacin, omeprazole, etizolamide/enalapril, olanzapine, metotrexate, bosentan, camostat/Benzbromarone, papaverin, benzarone, terbinafine, methylphenidate, buspiron, indomethacin, enalapril/metformin, olmesartan/amlozipine, varenicline, memantine, and cyproterone acetate ($n = 2$) (SI 24 and 72–97). During the early part of the study period, hepatitis C serology was not available, which made interpretation of the case reports more difficult and lead to exclusion of cases such as for oxyphenisatin.

Most of the single reports lacked important elements to evaluate for DI-AILH or were unconvincing. In many of these patients, autoantibodies, ANAs, and/or SMAs disappeared after the implicated drug had been discontinued (data not shown). Among these 27 drugs (a few drug combinations), only one fulfilled the criteria for probable DI-AILH, which was cyproterone acetate in one out of two reports (SI 97). Thus, despite many reports with single or two reports of the same drug, the
**TABLE 4**  Suspected DI-AILH associated with reports with adalimumab, etanercept, and efalizumab

| Age, years/gender, F/M | Drug     | Duration (months) | ANA | SIA | IgG high | Biopsy | Cortico-steroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
|------------------------|----------|-------------------|-----|-----|----------|--------|------------------|----------|---------|-----|-----|------------|------------------------|
| Grasland 2012 (SI 39)  | Adalimumab| 2.5               | Pos | Pos | Yes      | Yes    | Yes              | Yes      | No      | 7   | 8   | No         | 1,2,3,4                |
| Lucena 2011 (SI 24)    | Adalimumab| 1.5               | Pos | Neg | No       | N/A    | No               | No       | No      | 3   | 6   | No         | 1,2,4                  |
| Adar 2010 (SI 40)      | Adalimumab| 3                 | Pos | Neg | Yes      | Yes    | Yes              | Yes      | No      | 7   | 5   | Yes        | 1,2,3                  |
| Nakayama 2013 (SI 41)  | Adalimumab| 2                 | Pos | Neg | Yes      | Yes    | Yes              | No       | 7       | –   | –   | –          | –                      |
| Petriková 2015 (SI 42) | Adalimumab| 1.5               | Pos | Pos | Yes      | Yes    | Yes              | No       | No      | 7   | –   | –          | –                      |
| Rodrigues 2015 (SI 43) | Adalimumab| N/A               | Pos | Neg | Yes      | Yes    | Yes              | Yes      | No      | 7   | –   | –          | –                      |
| Miranda-Bautista 2019  | Adalimumab| 6                 | Pos | Neg | N/A      | Yes    | No               | No       | No      | 6   | 36  | No         | 1,4                    |
| Rösner 2013 (SI 45)    | Adalimumab| 9                 | Neg | Neg | No       | Yes    | Yes              | No       | Yes     | 3   | 84  | Yes        | 2,3                    |
| Rösner 2013 (SI 45)    | Adalimumab| 60                | Pos | Pos | No       | Yes    | Yes              | No       | No      | 5   | 96  | No         | 1,2,3,4                |
| Rösner 2013 (SI 45)    | Adalimumab| 12                | Pos | Neg | No       | Yes    | No               | No       | No      | 5   | 6   | No         | 1,2,4                  |
| Titos-Arcos 2012 (SI 46)| Adalimumab| 2                | Pos | Neg | No       | No     | No               | No       | No      | 5   | 24  | No         | 1,4                    |
| Fathalla 2008 (SI 47)  | Etanercept| 10                | Pos | Pos | Yes      | Yes    | Yes              | Yes      | No      | 7   | 3   | Yes        | 1,2,3                  |
| Harada 2008 (SI 48)    | Etanercept| 0,5               | Pos | Pos | Yes      | Yes    | Yes              | No       | No      | 7   | 28  | Yes        | 1,2,3                  |
| Primo 2010 (SI 49)     | Efalizumab | 20                | Pos | Pos | Yes      | Yes    | Yes              | Yes      | No      | 7   | 8   | Yes        | 1,2,3                  |
| Spanish DILI Reg       | Efalizumab | 2,6               | Pos | Neg | Yes      | Yes    | Yes              | No       | No      | –   | 6   | Yes        | 1,2,3                  |
association between drug intake and development of autoimmune features was in most cases unconvincing, and in some cases this was due to lack of important data.

Table 8 lists the clinical characteristics of DI-AILH cases according to the therapeutic class of culprit compounds. The mean duration of therapy before detection of elevated liver tests was 2.6 months, and most of those with DI-AILH due to conventional drugs were of female gender (79%). Liver biopsy was undertaken in most cases, and corticosteroids were used for the liver inflammation in most cases (Table 8).

**DISCUSSION**

The results of the current study demonstrate that mostly drugs that are immune modulators or affect the immune system such as interferon, imatinib, adalimumab, and methylprednisolone had convincing reports of DI-AILH. Statins and diclofenac were found to a lesser extent to have reports that appear to induce DI-AILH. Primarily statins were found to be suspected to trigger classical AIH, which was not seen with the other drugs with an exception of one case with adalimumab. In terms of HDS, khat and—more recently—Tinospora cordifolia appear to be able to induce DI-AILH. However, most single reports with a number of drugs and HDS that were suggested to cause DI-AILH were found to be unconvincing and lacked evidence of a relationship between the drugs as the etiology of abnormal liver tests with autoimmune features. Unfortunately, the current study does not answer the question of why these particular drugs induce in some patients an AIH-like pattern, which in most cases required corticosteroids and very rarely relapsed after stopping immunosuppression.

The major diagnostic challenge in the diagnosis of DI-AILH is to assign an etiological role of a specific drug. This issue has not only implications in the clinical scenario but also in drug development. Drugs that have been well documented to induce liver injury with autoimmune features as mentioned previously are methylpred, nitrofurantoin, hydralazine, and minocycline.[2,5,9,19,30,31] All of these drugs have a well-recognized ability to cause DILI in general, all of whom with more than 100 reports of liver injury.[32] Recently, infliximab has been shown to cause liver injury with autoimmune features.[7,33] Thus, there appears to be little doubt that methylpred, nitrofurantoin, hydralazine, minocycline, and infliximab can lead to DI-AILH[2,5,7,9,17,30,31] and were therefore not included in the current study. Furthermore, liver injury associated with immune checkpoint inhibitors was not included in the current study, as hepatotoxicity due to these agents is very rarely associated with autoimmune features and the histological injury is not reminiscent of idiopathic autoimmune hepatitis, and therefore appear to be in a separate category.[34] Accordingly, the recent
| Table 6 | Suspected DI-AILH associated with methylprednisolone |
|---------|----------------------------------------------------|
| Age, years/gender, F/M | Drug | Duration (months) | ANA | SMA | IgG high | Biopsy | Corticosteroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
| Salvi 2004 (SI 52) | 43/F | MPS | 1.5 | Pos | Neg | No | Yes | Yes | No | No | 4 | 2.5 | Yes | 1,2,3 |
| Takahashi 2008 (SI 53) | 43/F | MPS | 0.5 | Pos | Pos | No | Yes | Yes | No | No | 5 | 3 | Yes | 1,2,3 |
| Nociti 2018 (SI 54) | 24/F | MPS | 0.5 | Neg | Pos | No | Yes | No | No | No | 5 | 6 | No | 1,2,3,4 |
| Nociti 2018 (SI 54) | 19/F | MPS | 0.5 | Pos | Pos | Yes | Yes | Yes | Yes | No | No | 5 | 3 | Yes | 1,2,3 |
| Allgeier 2021 (SI 55) | 48/M | MPS | 1.5 | Pos | Neg | No | Yes | Yes | No | No | 5 | 9 | No | 1,2,3,4 |
| Allgeier 2021 (SI 55) | 26/F | MPS | 1.5 | Pos | Neg | No | Yes | Yes | No | No | 5 | 52 | No | 1,2,3,4 |
| Allgeier 2021 (SI 55) | 74/F | MPS | 0.5 | Pos | Neg | No | Yes | No | No | No | 5 | – | No | – |
| Allgeier 2021 (SI 55) | 49/F | MPS | 1.0 | Pos | Neg | No | Yes | Yes | No | No | 5 | 26 | No | 1,2,3,4 |
| Allgeier 2021 (SI 55) | 51/F | MPS | 1 | Pos | Neg | No | Yes | Yes | No | No | 5 | – | No | – |
| Allgeier 2021 (SI 55) | 23/F | MPS | 0.5 | Pos | Neg | No | No | No | No | No | 4 | – | No | 2,3,4 |
| Allgeier 2021 (SI 55) | 29/F | MPS | 0.5 | Pos | Neg | No | No | No | No | No | 4 | 14 | No | 2,3,4 |
| Allgeier 2021 (SI 55) | 51/F | MPS | 1.9 | Pos | Neg | No | No | Yes | No | No | 4 | – | No | 2,3,4 |
| Allgeier 2021 (SI 55) | 35/F | MPS | 0.5 | Pos | Neg | No | No | No | No | No | 4 | – | No | 2,3,4 |
| Allgeier 2021 (SI 55) | 35/F | MPS | 1.2 | Pos | Neg | No | Yes | Yes | No | No | 5 | – | No | – |
| Allgeier 2021 (SI 55) | 43/F | MPS | 0.7 | Pos | Neg | No | Yes | Yes | No | No | 5 | – | No | – |
| Allgeier 2021 (SI 55) | 20/F | MPS | 1.8 | Pos | Neg | No | Yes | Yes | No | No | 5 | 7 | No | 1,2,3,4 |

Abbreviation: MPS, methylprednisolone.
# Table 7

Suspected DI-AILH associated with HDS

| Age, years/gender, F/M | Drug                  | Duration (months) | ANA  | SIA  | IgG high | Biopsy | Corticosteroids | Other IS | Relapse | NSC | F-U | Still on IS | Criteria for DI-AILH |
|------------------------|-----------------------|-------------------|------|------|----------|--------|-----------------|----------|---------|-----|-----|-------------|----------------------|
| Ben Yahia 1993 (SI 56) | 37/F                  | Germander         | 0,75 | Neg  | Pos      | N/A    | Yes             | No       | No      | No  | 4   | 16          | No                   |
|                       | Ben Yahia 1993 (SI 56) | 45/F              | 6    | Pos  | Pos      | N/A    | Yes             | No       | No      | No  | 4   | 3           | No                   |
| Cohen 2004 (SI 57)    | 57/F                  | Black kohosh      | 0.75 | Pos  | Neg      | N/A    | Yes             | Yes      | Yes     | Yes | 5   | –           | Yes                  |
|                       | Guzman 2009 (SI 58)   | Black kohosh      | 6    | Pos  | Pos      | N/A    | Yes             | Yes      | Yes     | No  | 5   | 40          | Yes                  |
| Guzman 2009 (SI 58)   | 53/F                  | Black kohosh      | 12   | Neg  | Neg      | N/A    | Yes             | No       | No      | No  | 4   | 1.2         | Yes                  |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Neg  | Neg      | Yes    | Yes             | Yes      | Yes     | No  | 5   | 1           | Yes                  |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Neg  | Neg      | No     | Yes             | No       | No      | No  | 3   | 1           | Yes                  |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Pos  | N/A      | Yes    | Yes             | Yes      | Yes     | No  | 7   | –           | Yes                  |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Pos  | N/A      | Yes    | Yes             | Yes      | Yes     | No  | 6   | –           | Yes                  |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Neg  | Neg      | Yes    | Yes             | Yes      | No      | No  | 5   | –           | –                    |
| Riyaz 2014 (SI 59)    | –/M                   | Khat              | N/A  | Pos  | N/A      | Yes    | Yes             | Yes      | No      | No  | 5   | –           | –                    |
| Teisen 2016 (SI 60)   | 35/M                  | Khat              | N/A  | Neg  | Pos      | Yes    | Yes             | Yes      | Yes     | No  | 6   | 3           | No                   |
| Teisen 2016 (SI 60)   | 38/M                  | Khat              | N/A  | Neg  | Pos      | Yes    | Yes             | Yes      | Yes     | No  | 6   | 28          | No                   |
| Teisen 2016 (SI 60)   | 26/M                  | Khat              | N/A  | Neg  | Pos      | Yes    | Yes             | Yes      | Yes     | No  | 6   | 8           | No                   |
| Teisen 2016 (SI 60)   | 24/M                  | Khat              | N/A  | Neg  | Neg      | Yes    | Yes             | Yes      | Yes     | No  | 6   | 6           | Yes                  |
| Teisen 2016 (SI 60)   | 52/M                  | Khat              | N/A  | Neg  | Pos      | Yes    | Yes             | Yes      | No      | No  | 6   | 6           | Yes                  |
| Nagral 2021 (SI 61)   | 54/F                  | Tinospora cordifolia | 7   | Pos  | Neg      | No     | Yes             | Yes      | No      | No  | 5   | 12          | No                   |
| Nagral 2021 (SI 61)   | 38/M                  | Tinospora cordifolia | 6   | Pos  | Neg      | No     | Yes             | No       | No      | No  | 5   | 8           | No                   |
| Nagral 2021 (SI 61)   | 62/F                  | Tinospora cordifolia | 1   | Pos  | Pos      | N/A    | Yes             | Yes      | No      | No  | 5   | 12          | Yes                  |
| Nagral 2021 (SI 61)   | 56/F                  | Tinospora cordifolia | 0.75 | Neg  | Neg      | Yes    | Yes             | Yes      | No      | No  | 5   | 12          | No                   |
| Nagral 2021 (SI 61)   | 56/F                  | Tinospora cordifolia | 3   | Neg  | Neg      | Yes    | Yes             | No       | No      | No  | 5   | 2           | No                   |
| Sahney 2021 (SI 62)   | 49/F                  | Tinospora cordifolia | 2.8 | Pos  | Neg      | Yes    | Yes             | Yes      | No      | No  | 7   | 6           | No                   |
| Sahney 2021 (SI 62)   | 36/F                  | Tinospora cordifolia | 2   | Neg  | Neg      | Yes    | Yes             | No       | No      | No  | 5   | 3           | No                   |
| Sahney 2021 (SI 62)   | 68/F                  | Tinospora cordifolia | 2.4 | Pos  | Neg      | Yes    | Yes             | Yes      | No      | No  | 5   | 4           | Yes                  |

Abbreviation: HDS, herbal and dietary supplements.

*Developed primary sclerosing cholangitis.

(Continues)
| Clinical characteristics of DI-AILH cases according to the therapeutic class of culprit compounds |
|---------------------------------|-----------------|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                 | Statins | Interferons | Imatinib and other kinase inhibitors | Adalimumab, etanercept, and efalizumab | Diclofenac | Methylprednisolone | HDS |
| **N**                          | 24      | 37          | 10               | 15               | 7               | 14              | 24              |
| Fulfilling all four criteria for DI-AILH-like, n (%) | 4 (17)  | 8 (22)      | 4 (40)           | 2 (13)           | 3 (43)         | 5 (36)          | 6 (25)          |
| Median age, years (range)      | 59 (43–78) | 39 (11–68)  | 47 (17–68)       | 43 (9–56)        | 59 (19–76)     | 41 (20–74)      | 46 (24–68)      |
| Female, n (%)                  | 16 (67) | 32 (86)     | 6 (60)           | 14 (93)          | 5 (71)         | 15 (94)         | 12 (50)         |
| Duration of treatment months, median (range) | 4 (1.5–62) | 3 (0.5–312) | 2.8 (0.5–18)     | 2.8 (0.5–60)    | 2 (1.5–4)      | 1 (0.5–1.9)     | 2.8 (0.75–12)   |
| Positive ANA, n (%)            | 19 (90) | 29 (78)     | 6 (60)           | 14 (93)          | 6 (86)         | 15 (94)         | 11 (46)         |
| Positive SMA, n (%)            | 12 (75) | 30 (83)     | 1 (10)           | 6 (40)           | 3 (50)         | 2 (13)          | 8 (38)          |
| IgG > ULN, n (%)               | 11 (68) | 14 (70)     | 3 (42)           | 9 (64)           | 0              | 0              | 15 (83)         |
| Liver biopsy, n (%)            | 17 (85) | 23 (82)     | 8 (80)           | 13 (92)          | 7 (100)        | 12 (75)         | 23 (96)         |
| Corticosteroids, n (%)         | 16 (76) | 33 (89)     | 8 (80)           | 11 (73)          | 4 (57)         | 12 (75)         | 19 (79)         |
| Other IS, n (%)                | 9 (43)  | 17 (46)     | 1 (10)           | 5 (36)           | 1 (14)         | 0              | 9 (38)          |
| Relapse, n (%)                 | 7 (38)  | 0           | 0                | 1 (7.7)          | 0              | 0              | 0               |
| Time of follow-up months, mean | 19      | 27          | 18               | 26               | 15             | 16             | 6               |
| Still on IS, n (%)             | 12 (57) | 24 (70)     | 2 (22)           | 6 (50)           | 1 (14)         | 2 (14)         | 11 (52)         |

Abbreviation: ULN, upper limit of normal.
American guidelines on AIH have excluded liver injury associated with check point inhibitors as a phenotype of AIH. Indeed, it would not have been possible to use the same criteria for liver injury caused by immune checkpoint inhibitors as the other drugs.

As patients who present with different acute and chronic liver diseases can have associated autoantibodies in serum, including patients with DILI, it is obviously not sufficient for the diagnosis of DI-AILH to have a drug etiology and positive autoantibodies.

In the European Association for the Study of Liver (EASL) clinical guidelines for autoimmune hepatitis, the authors stated that “of the several diagnostic challenges associated with this disease, the issue of drug-induced (like) AIH is the most complex and is not fully understood.”

Previous studies have not been able to distinguish DI-AILH from idiopathic AIH, clinically, biochemically, immunologically, or histologically. In a study from the Mayo Clinic, the only feature that was found to distinguish these patients with DI-AILH from AIH was the lack of relapse after discontinuation of the IS in the former, whereas most of the other patients with AIH had a relapse of their AIH. Similarly, in a large cohort of infliximab-induced DILI, relapse was not observed in those treated with corticosteroids. Thus, the general rule of lack of relapse in patients treated with corticosteroids for DI-AILH was due to methylprednisolone, nitrofurantoin, hydralazine, minocycline, and infliximab. According to the clinical practice guidelines of AIH from the American Association for the Study of Liver Diseases and EASL, the DI-AILH clinical phenotype is considered to be associated with a lack of relapse, whereas when these patients experience a relapse they should be classified rather in the idiopathic AIH category.

However, it is conceivable that drugs can trigger classic AIH. In the current study, this was almost exclusively associated with statins, which were the only type of drugs that fulfilled criteria 5 of being suspected of inducing chronic AIH.

The criteria used in the current study relied on positive autoimmune markers with a histology compatible with AIH, incomplete recovery or worsening of liver tests after stopping the implicated agent, need for corticosteroids to improve the liver injury, and lack of relapse after stopping corticosteroids. At least three of four indicated possible, whereas the first four criteria were needed to define probable DI-AILH. The current criteria have limitations. It is conceivable that some patients who do not improve in liver tests might respond to corticosteroids, although they lack autoantibodies. It was also difficult in some reports to assess whether there was incomplete recovery of liver tests after stopping the implicated agent. Furthermore, it was not always easy to dismiss IS due to the underlying condition. Only two cases of liver injury associated with minocycline with autoimmune features have been reported to relapse after discontinuation of corticosteroids. Therefore, there have been exceptions in terms of minocycline, but to our knowledge relapse has not been reported after corticosteroid treatment of DI-AILH due to methylprednisolone, infliximab, and interferon alpha, and interferon beta, which was the most common type of drug found to induce DI-AILH, were not reported to have their IS discontinued in reports from 1989 to 2004. When this was first tried in 2006 and thereafter, it was always successful without relapse. Similarly, imatinib, a protein-tyrosine kinase inhibitor, was found to have several reports of convincing DI-AILH without a single case of relapse, suggesting that this type of drug does indeed induce DI-AILH, and not simply trigger classical AIH.

The proportion of females was high in drugs convincingly leading to DI-AILH in the current study (interferons [86%), imatinib [60%), adalimumab [90%), and methylprednisolone [94%]), which is in line with previous reports of DI-AILH. We do not have an explanation for the induction of DI-AILH by high-dose methylprednisolone, and it also appears to be able to induce liver injury without autoimmune features. We are not aware of other corticosteroids that can lead to DI-AILH.

Although a substantial number of cases of statin-induced DI-AILH was reported, only 4 of 24 (17%) probable DI-AILH cases were observed. There were a few convincing cases due to statins, and statins might be able to induce DI-AILH. Relapse was frequently observed in the statin reports, and it is conceivable that the statins might have triggered a classical AIH. Some was true for diclofenac: Three cases fulfilled the criteria of probable DI-AILH, but strangely enough all were from the early 1990s.

Although we were able to find a total of 38 reports of suspected HDS-induced DI-AILH, only two compounds were found to fulfill the criteria for probable DI-AILH. The use of khat and Tinospora cordifolia both had three probable DI-AILH cases reported. Interestingly, all except 1 patient (86%) using Tinospora cordifolia were female, whereas all khat (cathine and cathine are the active ingredients, structurally related to amphetamine)
users were male, as chewing khat leaves is a common social tradition especially among men. Khat has been reported to have serious hepatic complications and has been associated with the development of liver cirrhosis.\[41\]

There were various reasons for lack of fulfillment of criteria for DI-AILH in terms of both conventional drugs and HDS. In many of the reports, patients with DILI were described who had positive autoantibodies that spontaneously disappeared after discontinuation of the implicated agent. Furthermore, in some cases with very short drug exposure, drugs might have been consumed for symptoms of previously unrecognized AIH, and in several cases probably innocent bystanders who presented with idiopathic AIH. However, it was reported from the Spanish Hepatotoxicity Registry that among patients with at least two episodes of DILI caused by different drugs, 4 of 9 (44%) presented with AIH in the second episode.\[42\]

The current study has some strengths. A relatively large number of reports were analyzed systematically based on predetermined criteria. The proposed criteria also create some limitations, as they have not been validated and there is no consensus in the literature on their use. The major drawback of the analysis was a heterogenous and inconsistent presentation of the cases, which made interpretation of data difficult. Human leukocyte antigen typing was only presented in the NSC. The NSC have not been validated in acute liver injury with an autoimmune phenotype. Hepatol Commun. 2020;4:1651–63.

In conclusion, the criteria proposed in this study may help to distinguish the phenotype of DI-AILH from idiopathic AIH. Clinicians should strongly consider stopping corticosteroids in patients in biochemical remission from liver injury associated with drugs found to induce probable DI-AILH in the current study.

ACKNOWLEDGMENT

The authors would like to thank Maria Angeles, secretary for the Department of Medicine, Faculty of Medicine, University of Malaga for expert secretarial assistance.

CONFLICT OF INTEREST

Nothing to report.

REFERENCES
1. Belloc C, Gauffre A, Andre C, Beaune PH. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics. 1997;7:181–6.
2. Sotaniemi EA, Hakkanen OT, Ahokas JT, Pelkonen RO, Ahlqvist J. Hepatic injury and drug metabolism in patients with alpha-methylidopa-induced liver damage. Eur J Clin Pharmacol. 1977;12:429–35.
3. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J. 2002;4:184–6.
4. Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, et al. Drug induced hepatitis with autoimmune features during minocycline therapy. Intern Med. 2003;42:48–52.
5. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.
6. de Boer YS, Kosinski AS, Urban TJ, Zhao L, Long N, Chalasani N, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15:103–12.
7. Björnsson HK, Gudbjörnsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol. 2022;76:86–92.
8. Guzman G, Kallwitz ER, Wojewoda C, Chennuri R, Barnes J, Layden TJ, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Report Med. 2009;2009:918156.
9. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–76.
10. Andrade RJ, Robles-Diaz M, Castiella A. Characterizing drug-induced liver injury with autoimmune features. Clin Gastroenterol Hepatol. 2016;14:1844–5.
11. De Boer YS, Kosinski AS, Urban TJ, Zhao L, Long N, Chalasani N, et al. Reply. Clin Gastroenterol Hepatol. 2016;14:1845–6.
12. Bernal W, Ma Y, Smith HM, Portmann B, Weldon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:684–70.
13. Stephens C, Castiella A, Gomez-Moreno EM, Otazua P, Lopez-Nevot MA, Zapata E, et al. Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leukocyte antigen alleles. Pharmacogenet Genomics. 2016;26:414–22.
14. Lammert C, Zhu C, Lian Y, Raman J, Eckert G, Li Q-Z, et al. Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype. Hepatol Commun. 2020;4:1651–63.
15. Philips CA, Paramaguru R, Joy AK, Antony KL, Augustine P. Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury—a single-center experience from southern India. Indian J Gastroenterol. 2018;37:9–17.
16. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2004;99:1316–20.
17. Ravi S, Shoreibah M, Raff E, Bloomer J, Kakati D, Rasheed K, et al. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease. Dig Dis Sci. 2015;60:3788–93.
18. Terzioli Beretta-Piccoli B, Di Bartolomeo C, Deleondari G, Grondana AG, Silvestri T, Tesei C, et al. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. J Autoimmun. 2019;102:89–95.
19. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980;92:14–9.
20. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998;152:1132–6.
21. Goldstein GB, Lam KC, Mistilis SP. Drug induced active chronic hepatitis. Am J Dig Dis. 1973;18:177–84.
22. Castiella A, Lucena MI, Zapata EM, Otazua P, Andrade RJ. Drug-induced autoimmune-like hepatitis: a diagnostic challenge. J Gastroenterol Hepatol. 2011;26:562–7.
23. Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Gastroenterol. 2014;20:15362–8.
24. Weiler-Norrman C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.
25. deLemos AS, Foureaux DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis. 2014;34:194–204.
26. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. drug-induced liver injury. Hepatology. 2011;54:931–9.
27. Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15:1635–6.
28. Stephens C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, Ortega-Alonso A, Sanabria-Cabrera J, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Gastroenterol Hepatol. 2021;36:86–97.
29. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.
30. Mansilla-Tinoco R, Harland SJ, Ryan PJ, Bernstein RM, Dollery CT, Hughes GR, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J. 1982;284:936–9.
31. Harmon EG, McConnie R, Kesanav A. Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis. Pediatr Gastroenterol Hepatol Nutr. 2018;21:347–50.
32. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports. Hepatology. 2016;63:590–603.
33. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11:558–64.
34. De Martin E, Michot J-M, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–90.
35. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722.
36. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.
37. Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009;43:787–90.
38. Heurgue-Berlot A, Bernard-Chabert B, Diebold MD, Thiénè G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci. 2011;56:2504–6.
39. van Gerven NMF, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58:141–7.
40. Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, et al. Liver injury after methylprednisolone pulses: a disputable cause of hepatotoxicity. A case series and literature review. United Gastroenterol J. 2019;7:825–37.
41. Mahamoud HD, Muse SM, Roberts LR, Fischer PR, Torbenson MS, Fader T. Khat chewing and cirrhosis in Somaliland: case series. Afr J Prim Health Care Fam Med. 2016;8:e1–4.
42. Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55:820–7.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Björnsson ES, Medina-Caliz I, Andrade RJ, Lucena MI. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6:1895–1909. https://doi.org/10.1002/hep4.1959